Targeted treatment slows progression of rare connective tissue tumor

A drug called sorafenib stopped progression of desmoid tumors for 80 percent of patients taking the drug over a two-year period as part of a phase 3 trial.

About admin

Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge. Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →

Leave a Reply

Your email address will not be published. Required fields are marked *